Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8293176 | 0.91 | CYP19A1 (0.57) | CYP19A1CYP11B2TRPA1 | |
| SCHEMBL4864390 | 0.91 | CYP19A1 (0.57) | CYP19A1CYP11B2TRPA1LOXL2GBA1 | |
| SCHEMBL16612734 | 0.89 | CYP19A1 (0.52) | CYP19A1CYP11B2TRPA1LOXL2ALDH1A1 | |
| SCHEMBL14174294 | 0.89 | CYP19A1 (0.52) | CYP19A1CYP11B2TRPA1ALDH1A1 | |
| SCHEMBL8910496 | 0.89 | CYP19A1 (0.55) | CYP19A1CYP11B2TRPA1 | |
| SCHEMBL803096 | 0.86 | CYP19A1 (0.49) | CYP19A1CYP11B2TRPA1ALDH1A1 | |
| SCHEMBL2109582 | 0.85 | GBA1 (0.66) | CYP19A1CYP11B2GBA1CYP2D6 | |
| SCHEMBL8890474 | 0.84 | CYP19A1 (0.52) | CYP19A1CYP11B2TRPA1ALDH1A1 | |
| SCHEMBL13681385 | 0.84 | CYP19A1 (0.47) | CYP19A1CYP11B2TRPA1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1550607 | 0.83 | GBA1 (0.63) | CYP19A1CYP11B2GBA1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103517710-B | For the compound of kinases regulation | 普莱希科公司 | 2017-05-31 | — | — | CN | disclosed |
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7867980-B2 | Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100184746-A1 | LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD | 2010-07-22 | — | — | US | disclosed |
| EP-2166015-A1 | LINCOSAMIDE DERIVATIVE, AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| EP-1654268-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1644393-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | VICURON PHARMACEUTICALS INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005012320-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005007665-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-11-18 | — | — | US | disclosed |
| US-5430155-A | Viricides, treatment of AIDS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-04 | — | — | US | disclosed |
| US-5294720-A | Viricides | THE DUPONT MERCK PHARMACEUTICAL CO. (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0532693-A1 | 1,4-DIAMINO-2,3-DIHYDROXYBUTANES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | NRDC, NISCH, CLSPN | CYP19A1 4359/4885CYP11B2 4493/4885TRPA1 3306/4885 |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | CYP19A1 3032/4885CYP11B2 2798/4885TRPA1 2289/4885 |
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PAM, MLYCD, PPT1 | CYP19A1 4131/4885CYP11B2 3331/4885TRPA1 2199/4885 |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | LCLAT1, NRDC, LAS1L | CYP19A1 4441/4885CYP11B2 4249/4885TRPA1 3275/4885 |
| US-20100184746-A1 | LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | SIRT6, LAS1L, MRPS18A | CYP19A1 3584/4885CYP11B2 3827/4885TRPA1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.